Supernus Pharmaceuticals Inc., of Rockville, Md., said the FDA granted tentative approval to the supplemental NDA requesting a label expansion for Trokendi XR (topiramate, extended release) to include prophylaxis of migraine headache in adults. Read More
Xenetic Biosciences Inc., of Lexington, Mass., said it was cleared by the FDA to start a phase II trial of Virexxa (sodium cridanimod), a small-molecule immunomodulator and interferon inducer, in conjunction with progestin therapy for the treatment of endometrial cancer in women with recurrent or persistent disease who have failed progestin monotherapy. Read More
Edible nanoparticles made from ginger reduced pro-inflammatory cytokines, increased anti-inflammatory cytokines, reduced acute colitis, enhanced intestinal repair and prevented chronic colitis and colitis-associated cancer in mouse models of Crohn's disease and ulcerative colitis, which together make up inflammatory bowel disease (IBD). Read More
Helix Biopharma Corp., of Aurora, Ontario, said it closed a private placement financing for aggregate gross proceeds of approximately C$1 million (US$776,771). Read More
The first critical limb ischemia (CLI) patients have been enrolled in an FDA trial, under an investigational new drug (IND) application, for the Bullfrog micro-infusion device from Mercator Medsystems Inc. Read More
Three-year-old Rasna Therapeutics Inc. took the reverse merger route to the public markets, joining with Canadian travel company Active With Me Inc. to gain a listing on the Over-the-Counter Pink market, where it will continue to trade, for now, under the ticker ATVM. Read More
Two Canadian engineers are taking nanotechnology to new levels in the fight against cancer. Warren Chan at the University of Toronto's biomedical engineering department uses DNA sequencing to change the shape, size and chemistry of modular nanoparticles to target cancer in specific organs. Read More
Chronic pain is an enormous problem, affecting about 10 to 15 percent of the adult population. Another enormous problem? Opioid painkiller addiction, which kills about 30,000 Americans annually. Read More
Clovis Oncology Inc.'s publicly known showing with oral PARP inhibitor rucaparib in advanced ovarian cancer turned up in platinum-sensitive patients, which makes comparisons tough with Astrazeneca plc's same-class Lynparza (olaparib). Read More
